Literature DB >> 19139695

Pharmaceuticals companies' medication assistance programs: potentially useful but too burdensome to use?

Maria Pisu1, Joshua Richman, Jeroan J Allison, O Dale Williams, Catarina I Kiefe.   

Abstract

OBJECTIVES: This study examined how physicians perceive pharmaceutical companies' medication assistance programs (MAPs).
METHODS: The study was conducted using a survey of 373 primary care physicians from four southern states; they were surveyed within the formative evaluation phase of a larger study (MI-Plus). Respondents were queried about use and usefulness of MAPs for patients who cannot afford drugs, and barriers to using them. Bivariate associations between physician-level variables (patients without drug coverage) and usefulness and barriers to using MAPs were assessed using Chi square tests. Independence of associations was assessed using multiple logistic regressions.
RESULTS: Of the 364 (97.6%) respondents who used MAPs, 70% used them regularly, the rest occasionally; 63% found MAPs very useful in caring for patients who could not afford drugs. About 89% reported one or more barriers to using MAPs; 47% saw "inability of patients to apply directly;" and 57% saw "enrollment process being time-consuming for staff" as barriers. Compared to physicians with fewer elderly patients without drug coverage, those with more of these patients were less likely to find MAPs very useful; less likely to report no barriers to using MAPs; and more likely to see "low income thresholds" and "inability of patients to apply directly" as barriers.
CONCLUSION: While MAPs are considered useful in caring for patients in need of assistance, there are many barriers to their use. Pharmaceutical companies should address these barriers. Limitations include a low response rate (about 10%).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139695      PMCID: PMC3858081          DOI: 10.1097/SMJ.0b013e31818bbe5e

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  17 in total

1.  A cancer drug shows promise, at a price that many can't pay.

Authors:  Alex Berenson
Journal:  N Y Times Web       Date:  2006-02-15

2.  Pharmaceutical patient assistance programs: don't look a gift horse in the mouth or there's no such thing as a free lunch.

Authors:  Norman V Carroll
Journal:  J Manag Care Pharm       Date:  2007-09

3.  Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.

Authors:  Jeanne M Madden; Amy J Graves; Fang Zhang; Alyce S Adams; Becky A Briesacher; Dennis Ross-Degnan; Jerry H Gurwitz; Marsha Pierre-Jacques; Dana Gelb Safran; Gerald S Adler; Stephen B Soumerai
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

4.  Establishing an on-site pharmacy in a community health center to help indigent patients access medications and to improve care.

Authors:  Larry A Dent; Timothy P Stratton; Gayle A Cochran
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 May-Jun

5.  Pharmaceutical manufacturer assistance programs.

Authors:  Marie A Chisholm; Joseph T DiPiro
Journal:  Arch Intern Med       Date:  2002-04-08

6.  Accessing patient assistance programs to meet clients' medication needs.

Authors:  K Williams
Journal:  J Am Acad Nurse Pract       Date:  2000-06

7.  Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease.

Authors:  M D Schoen; R J DiDomenico; S E Connor; J E Dischler; J L Bauman
Journal:  Pharmacotherapy       Date:  2001-12       Impact factor: 4.705

8.  Patient-reported underuse of prescription medications: a comparison of nine surveys.

Authors:  Duane M Kirking; James A Lee; Jeffrey J Ellis; Becky Briesacher; Patrick L McKercher
Journal:  Med Care Res Rev       Date:  2006-08       Impact factor: 3.929

9.  Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.

Authors:  Chien-Wen Tseng; Robert H Brook; Emmett Keeler; Carol M Mangione
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  Outpatient medication assistance program in a rural setting.

Authors:  Gary N Harmon; John Lefante; Wendy Roy; Keith H Ashby; Danny Jackson; David Barnard; Allen Smart; Larry Webber
Journal:  Am J Health Syst Pharm       Date:  2004-03-15       Impact factor: 2.637

View more
  6 in total

1.  Medication adherence among rural, low-income hypertensive adults: a randomized trial of a multimedia community-based intervention.

Authors:  Michelle Y Martin; Young-il Kim; Polly Kratt; Mark S Litaker; Connie L Kohler; Yu-Mei Schoenberger; Stephen J Clarke; Heather Prayor-Patterson; Tung-Sung Tseng; Maria Pisu; O Dale Williams
Journal:  Am J Health Promot       Date:  2011 Jul-Aug

2.  Pharmaceutical assistance programs to support smoking cessation medication access.

Authors:  Angie Leon-Salas; Jamie J Hunt; Kimber P Richter; Niaman Nazir; Edward F Ellerbeck; Theresa I Shireman
Journal:  J Am Pharm Assoc (2003)       Date:  2016-11-03

Review 3.  What is the evidence for pharmaceutical patient assistance programs? A systematic review.

Authors:  Tisha M Felder; Nynikka R Palmer; Lincy S Lal; Patricia Dolan Mullen
Journal:  J Health Care Poor Underserved       Date:  2011-02

4.  Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center.

Authors:  Tisha M Felder; Lincy S Lal; Charles L Bennett; Frank Hung; Luisa Franzini
Journal:  Community Oncol       Date:  2012-02-10

5.  Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.

Authors:  Limin Gao; Jivin Joseph; Marcelle Santoro-Levy; Alan S Multz; Vladimir K Gotlieb
Journal:  Hosp Pharm       Date:  2016-07

6.  Medication assistance programs: do all in need benefit equally?

Authors:  Maria Pisu; Katie Crenshaw; Ellen Funkhouser; Midge Ray; Catarina I Kiefe; Kenneth Saag; Cynthia LaCivita; Jeroan J Allison
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.